Table 3.
Comparison of SR Versus SRB in All Reported Recurrence Events and 2- and 3-Year Recurrence End Points
| Event | Intention-to-Treat Cohort (n = 222) |
Per-Protocol Cohort (n = 212) |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SR (n = 114) |
SRB (n = 108) |
P* | SR (n = 108) |
SRB (n = 104) |
P* | |||||
| No. of Patients | % | No. of Patients | % | No. of Patients | % | No. of Patients | % | |||
| All reported events | ||||||||||
| LR | 16 | 14.0 | 18 | 16.7 | .59 | 16 | 14.8 | 18 | 17.3 | .62 |
| LRD | 49 | 43.0 | 53 | 49.1 | .36 | 47 | 43.5 | 50 | 48.1 | .51 |
| RR | 10 | 8.8 | 12 | 11.1 | .56 | 9 | 8.3 | 12 | 11.5 | .43 |
| DR | 13 | 11.4 | 13 | 12.0 | .88 | 13 | 12.0 | 13 | 12.5 | .92 |
| Any recurrence (local, regional, distant) | 30 | 26.3 | 29 | 26.9 | .93 | 29 | 26.9 | 29 | 27.9 | .87 |
| OS | 70 | 61.4 | 60 | 55.6 | .38 | 66 | 61.1 | 59 | 56.7 | .52 |
| Recurrence end point | ||||||||||
| LR at 2 years | 14 | 12.3 | 10 | 9.3 | .47 | 14 | 13.0 | 10 | 9.6 | .44 |
| LR at 3 years | 14 | 12.3 | 13 | 12.0 | .96 | 14 | 13.0 | 13 | 12.5 | .92 |
| LRD at 3 years | 37 | 32.5 | 33 | 30.6 | .76 | 36 | 33.3 | 32 | 30.8 | .69 |
| RR at 3 years | 8 | 7.0 | 9 | 8.3 | .71 | 7 | 6.5 | 9 | 8.7 | .55 |
| DR at 3 years | 10 | 8.8 | 12 | 11.1 | .56 | 10 | 9.3 | 12 | 11.5 | .59 |
| Any recurrence (local, regional, distant) at 3 years | 24 | 21.1 | 22 | 20.4 | .90 | 23 | 21.3 | 22 | 21.2 | .98 |
| OS at 3 years | 81 | 71.1 | 77 | 71.3 | .97 | 76 | 70.4 | 74 | 71.2 | .90 |
Abbreviations: DR, distant recurrence; LR, local recurrence; LRD, local recurrence/death; OS, overall survival; RR, regional recurrence; SR, sublobar resection; SRB, sublobar resection with brachytherapy.
*
χ2 test.